GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lifeward Ltd (NAS:LFWD) » Definitions » Debt-to-EBITDA

LFWD (Lifeward) Debt-to-EBITDA : -0.08 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Lifeward Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lifeward's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.94 Mil. Lifeward's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.05 Mil. Lifeward's annualized EBITDA for the quarter that ended in Sep. 2024 was $-12.70 Mil. Lifeward's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lifeward's Debt-to-EBITDA or its related term are showing as below:

LFWD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.71   Med: -0.3   Max: -0.05
Current: -0.06

During the past 12 years, the highest Debt-to-EBITDA Ratio of Lifeward was -0.05. The lowest was -0.71. And the median was -0.30.

LFWD's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.54 vs LFWD: -0.06

Lifeward Debt-to-EBITDA Historical Data

The historical data trend for Lifeward's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifeward Debt-to-EBITDA Chart

Lifeward Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.65 -0.14 -0.09 -0.05 -0.09

Lifeward Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.09 -0.07 -0.09 -0.08

Competitive Comparison of Lifeward's Debt-to-EBITDA

For the Medical Devices subindustry, Lifeward's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifeward's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lifeward's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lifeward's Debt-to-EBITDA falls into.



Lifeward Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lifeward's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.296 + 0.607) / -21.765
=-0.09

Lifeward's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.936 + 0.045) / -12.696
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Lifeward  (NAS:LFWD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Lifeward Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lifeward's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifeward Business Description

Traded in Other Exchanges
N/A
Address
3 Hatnufa Street, P.O. Box 161, Floor 6, Yokneam Ilit, ISR, 2069203
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
Executives
Lawrence J Jasinski director, officer: Chief Executive Officer SOTEIRA INC., 14 TECH CIRCLE, NATICK MA 01760
Jeannine Lynch officer: VP of Market Access & Strategy C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., P.O. BOX 161, YOKNEAM ILIT L3 20692203
Turk Joseph E Jr director NXSTAGE MEDICAL INC, 439 SOUTH UNION STREET 5TH FLOOR, LAWRENCE MA 01843
Michael A Lawless officer: Chief Financial Officer C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., FLOOR 6, YOKNEAM ILIT L3 2069203
Lind Global Fund Ii Lp 10 percent owner 444 MADISON AVENUE, 41ST FLOOR, NEW YORK NY 10022
Lind Global Macro Fund Lp 10 percent owner 444 MADISON AVE, FLOOR 41, NEW YORK NY 10022
Jeff Dykan director KOCHAV YOKNEAM BUILDING, FLOOR 6, P.O. BOX 161, YOKNEAM ILIT L3 20692
Aryeh Dan director KOCHAV YOKNEAM BUILDING, FLOOR 6, P.O. BOX 161, YOKNEAM ILIT L3 20692
Charles Remsberg officer: Chief Sales Officer C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., FLOOR 6, YOKNEAM ILIT L3 2069203
Randel Richner director C/O REWALK ROBOTICS, LTD., 3 HATNUFA ST. 6TH FL. P.O. BOX 161, YOKNEAM L3 2069203
Poduska John William Sr director 295 MEADOWBROOK RD, WESTON MA 02493
Yasushi Ichiki director KOCHAV YOKNEAM BUILDING, FLOOR 6, P.O. BOX 161, YOKNEAM ILIT L3 20692
Yohanan Engelhardt director 3 HATNUFA ST., FLOOR 6, YOKNEAM ILIT L3 2069203
Hadar Levy director C/O REWALK ROBOTICS LTD., 3 HATNUFA ST., FLOOR 6, YOKNEAM ILIT L3 2069203
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355